Non-PVC IV Bags Market, sustaining a 5.13% CAGR, is anticipated to reach USD 3.041 billion in 2031 from USD 2.252 billion in 2025.
| Report Metric | Details |
|---|---|
| Study Period | 2021 to 2031 |
| Historical Data | 2021 to 2024 |
| Base Year | 2025 |
| Forecast Period | 2026 – 2031 |
| Companies |
|
The non-PVC IV bags market is anticipated to grow at a steady pace throughout the forecast period. Intravenous bags produced from substances other than polyvinyl chloride (PVC) are known as non-PVC IV bags. Non-PVC IV bags are often created from substances that are less dangerous to human health, such as polyolefins, polyurethane, and polyethersulfone. The rising number of cancer cases and other chronic diseases such as kidney failure are major factors in the non-PVC IV bags market as the therapy in the treatments in these conditions requires IV bags.
Rising Cancer Cases
The non-PVC IV bags market is impacted by the growth in cancer cases in the population as well as the surge in demand for oncology processes, particularly for chemotherapy and targeted drug delivery. For instance, one in six deaths, or around 10 million deaths, was due to cancer in 2020, making it the top cause of death globally as per the WHO. In low and lower-middle-income nations, cancer-causing infections including the human papillomavirus (HPV) and hepatitis are estimated to be the cause of 30% of cancer cases. Non-PVC IV bags are less harmful concerning the contamination thus it is safe to use non-PVC IV bags.
Growing Burden of Chronic Diseases
The growing prevalence of chronic diseases such as kidney failure which require dialysis is expected to drive the non-PVC IV bags market in the coming years. For instance, in the United States, 37 million adults which is more than 1 in 7 have chronic kidney disease (CKD). The risk of CKD is even higher for Americans who have either diabetes or high blood pressure, the two main causes of kidney disease. Moreover, chronic obstructive pulmonary disease (COPD), the third highest cause of mortality globally, kills approximately 90% of those under the age of 70 in low- and middle-income (LMIC) countries, according to World Health Organisation (WHO) updates 2022. Due to the predicted rise in demand for non-PVC IV bags used to provide intravenous fluids to patients undergoing heart surgery and those being treated for acute exacerbations, the market is expected to develop.
Government Efforts to Increase the Use of Non-PC IV Bags
The non-PVC IV bags market is also being boosted by rigorous regulations governing the use and disposal of PVC and improved healthcare infrastructure in developing nations. It has been determined by several government agencies and expert panels in Europe, the US, Canada, and Japan that several medical treatments that expose patients to DEHP may be harmful to their health. For instance, to protect premature infants and newborns, the German Federal Institute for Drugs and Medical Equipment (BfArM) advises against using medical equipment made of DEHP-softened PVC. Additionally, BfArM asks producers of medical devices to disclose the presence of DEHP in their goods and to invest more time and energy in creating safer substitutes.
These growth factors mentioned above are predicted to provide an immense opportunity in the non-PVC IV bags market expansion. Apart from these factors, the growing awareness among patients about the harmful effects of plastic bags further indicates the growth in the non-PVC IV bags market. Packaging frequently uses PVC materials. However, because they cannot decompose, their disposal has a detrimental effect on the environment. Due to growing environmental concerns, eco-friendly PVC replacements are being developed, which is fueling the expansion of the non-PVC IV bag market globally. For instance, to advance sustainability in healthcare across Europe, VinylPlus Med officially inaugurated its pilot medical PVC recycling program in Belgium in October 2021. This program will recycle discarded single-use PVC medical devices, such as oxygen and anaesthetic masks, tubing, IVs, and dialysis bags.
Few factors are expected to limit the non-PVC IV bags market growth. The leached DEHP molecules from the PVC tube during intravenous infusion of aqueous drug solutions produce many harmful health effects, including but not limited to a disruption in human metabolism. Additionally, non-PVC infusion sets do not carry the DEHP molecules, which causes unfavourable health effects.
North America is Expected to Grow Significantly
The North American region is supposed to hold a significant share of the non-PVC IV bags market during the forecast period. Various factors attributed to such a share are rising cancer cases, awareness about the hazardous effects of PVC IV bags, and stringent government regulations. For instance, around 1.9 million new cancer cases are anticipated to be diagnosed in 2023 in the US as per the American Cancer Society. Using alternatives to DEHP-containing devices for specific, susceptible individuals is advised by the US Food and Drug Administration, according to an FDA Safety Assessment and a Public Health Notification. Moreover, the presence of market leaders such as Baxter and ICU Medical is further predicted to propel the non-PVC IV bags market in the region.
Baxter offers a range of acute, nutritional, renal, and surgical care products to advance healthcare around the globe. It offers more than 200 active codes for fluid therapy such as 0.9% sodium chloride injection in both Viflex and Viaflo containers (non-PVC), dextrose for injection, lactated ringers & ringers, OSMITROL, Plasmalyte, sterile water, and potassium chloride in dextrose & sodium injections. It also provides an IV solution for the drug reconstitution system.
ICU Medical, a US-based medical company focussed on IV therapy. Its IV solutions are produced in two US plants with reliable delivery in just one to two days in the US. It offers Supercath 5 IV Catheter, Y-Connector, Vial Adapter with Clave™, Double Female Connector, Supercath 5 IV Catheter, and others.
Report Metric | Details |
Non-PVC IV Bags Market Size in 2025 | USD 2.252 billion |
Non-PVC IV Bags Market Size in 2030 | USD 2.914 billion |
Growth Rate | CAGR of 5.29% |
Study Period | 2020 to 2030 |
Historical Data | 2020 to 2023 |
Base Year | 2024 |
Forecast Period | 2025 – 2030 |
Forecast Unit (Value) | USD Billion |
Segmentation |
|
Geographical Segmentation | North America, South America, Europe, Middle East and Africa, Asia Pacific |
List of Major Companies in the Non-PVC IV Bags Market |
|
Customization Scope | Free report customization with purchase |
Non-PVC IV Bags Market Segmentation
By Type
Single Chamber
Multi-Chamber
By Material
Ethylene Vinyl Acetate (EVA)
Polypropylene (PP)
Copolyester Ether
By Capacity
Up to 50 ml
50 to 100 ml
Greater than 100 ml
By End-User
Hospitals
Specialty Clinics
Others
By Geography
North America
United States
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
Germany
France
United Kingdom
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Others
Asia Pacific
China
India
Japan
South Korea
Indonesia
Thailand
Others